



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 65-235

Food and Drug Administration  
Rockville MD 20857

NOV 14 2005

Sandoz Inc.  
Attention: Beth Brannan  
Director, Drug Regulatory Affairs  
2555 W. Midway Blvd.  
Broomfield, CO 80038

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated June 30, 2004, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Cefprozil Tablets USP, 250 mg and 500 mg. We note that this product is subject to the exception provisions of Section 125(d)(2) of Title I of the Food and Drug Administration Modernization Act of 1997.

Reference is also made to your amendments dated March 10, April 11, April 19, April 25, April 26, September 8, and October 19, 2005.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Cefprozil Tablets USP, 250 mg and 500 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Cefzil<sup>®</sup> Tablets, 250 mg and 500 mg, respectively, of Bristol Myers Squibb Company Pharmaceutical Research Institute). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.


Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications (HFD-42) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Robert H. Buehler" with a large flourish at the end.

Gary Buehler

Director

Office of Generic Drugs

Center for Drug Evaluation and Research